TY - JOUR
T1 - Screening for Adiponectin Receptor Agonists and their Metabolites in Urine and Dried Blood Spots
AU - Dib, Josef
AU - Tretzel, Laura
AU - Piper, Thomas
AU - Lagojda, Andreas
AU - Kuehne, Dirk
AU - Schänzer, Wilhelm
AU - Thevis, Mario
PY - 2017/10/1
Y1 - 2017/10/1
N2 - AdipoRon and 112254 represent two known synthetic adiponectin receptor (adipoR) agonists. Although AdipoRon is the more potent compound, both have physiological properties that are similar to adiponectin - an adipokine with antidiabetic and antiatherogenic effects. Several transcriptional regulators are activated by adipoR-agonists leading to increased mitochondrial DNA content in vitro, an effect that can be abused by athletes for performance enhancing purposes. In the context of preventive anti-doping research, detection of AdipoRon and 112254 in routine doping control specimens would be valuable. Here, we describe our process for incorporating AdipoRon and 112254 into routine doping control methods involving urine and dried blood spot (DBS) analysis. Method validation including evaluation of specificity, limit of detection, identification capability, carryover, matrix interference, recovery, interday and intraday precision and linearity to standards provided by WADA. For identification in human urine, a liquid chromatography-tandem mass spectrometry-based testing approach was implemented for both adipoR agonists and two respective phase-I metabolites. Recovery of 85–104%, satisfactory limits of detection (i.e., 0.5–1 ng/mL), and imprecision values over three days at three concentration levels of
AB - AdipoRon and 112254 represent two known synthetic adiponectin receptor (adipoR) agonists. Although AdipoRon is the more potent compound, both have physiological properties that are similar to adiponectin - an adipokine with antidiabetic and antiatherogenic effects. Several transcriptional regulators are activated by adipoR-agonists leading to increased mitochondrial DNA content in vitro, an effect that can be abused by athletes for performance enhancing purposes. In the context of preventive anti-doping research, detection of AdipoRon and 112254 in routine doping control specimens would be valuable. Here, we describe our process for incorporating AdipoRon and 112254 into routine doping control methods involving urine and dried blood spot (DBS) analysis. Method validation including evaluation of specificity, limit of detection, identification capability, carryover, matrix interference, recovery, interday and intraday precision and linearity to standards provided by WADA. For identification in human urine, a liquid chromatography-tandem mass spectrometry-based testing approach was implemented for both adipoR agonists and two respective phase-I metabolites. Recovery of 85–104%, satisfactory limits of detection (i.e., 0.5–1 ng/mL), and imprecision values over three days at three concentration levels of
U2 - 10.1016/j.clinms.2017.10.002
DO - 10.1016/j.clinms.2017.10.002
M3 - Journal articles
SN - 2376-9998
VL - 6
SP - 13
EP - 20
JO - Clinical mass spectrometry
JF - Clinical mass spectrometry
ER -